New BioSpace tallies show fewer biopharma layoffs or projected cuts in Q1 2026 versus Q1 2025, though total affected employees increased, driven largely by Viatris’ plan to reduce up to 10% of its global workforce. The data point suggests hiring is stabilizing at some companies after prior restructuring waves. The report also notes that employee impacts remained elevated at Evotec due to a strategic reorganization shrinking its footprint from 14 sites to 10. Even with a slightly slower pace of workforce reductions year over year, the overall number of employees impacted rose. The staffing picture matters for pipeline execution and dealmaking capacity, as workforce planning increasingly reflects whether funding conditions have normalized or remain volatile.